Skip to main content
. Author manuscript; available in PMC: 2021 Jul 19.
Published in final edited form as: Cancer Prev Res (Phila). 2020 Jan 27;13(4):411–422. doi: 10.1158/1940-6207.CAPR-19-0424

Table 2. Description of tamoxifen knowledge and psychological data.

Mean (± SD) for continuous variables; % (95% CI) for categorical variables
Baseline (n= 408) n
Received a leaflet about tamoxifen
Yes 71.1 (66.4, 75.4) 290
No 25.7 (21.6, 30.3) 105
Unsure 3.2 (1.7, 5.4) 13
Knowledge
Potential benefit and harms of using tamoxifen +
Yes 15.7 (12.2, 19.7) 60
No 84.3 (80.3, 87.8) 323
Missing, n 25
Tamoxifen can reduce breast cancer risk
Yes 60.9 (55.8, 65.7) 238
No 39.1 (34.3, 44.2) 153
Missing, n 17
Tamoxifen can increase risk of menopausal symptoms
Yes 50.1 (45.1, 55.2) 197
No 49.9 (44.8, 54.9) 196
Missing, n 15
Tamoxifen can increase risk of blood clotting
Yes 49.7 (44.7, 54.8) 193
No 50.3 (45.2, 55.3) 195
Missing, n 20
Tamoxifen can increase risk of endometrial cancer
Yes 27.3 (22.9, 32.0) 107
No 72.7 (68.0, 77.1) 285
Missing, n 16
Satisfaction with healthcare professional, mean ± SD 19.30 (3.77) 375
Missing, n 33
Felt informed about tamoxifen
Yes 87.1 (83.4, 90.2) 351
No 12.9 (9.8, 16.6) 52
Missing, n 5
Three month follow-up (n = 258)
Subjective decisional quality, Mean ± SD 17.03 ± 1.87 146
‘Still deciding’, n 111
Missing, n 1

Key: CI, Confidence Interval; SES, Socioeconomic status; SD, Standard deviation.

+= This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and three potential harms of tamoxifen (increased risk of menopausal symptoms, blood clotting and endometrial cancer).